GLP-1 Drugs May Help People Stop Drinking

GLP-1 Receptor Agonists Could Help You Ditch the Drink. Researchers have found that the same drugs used to treat diabetes and obesity may offer a new path to sobriety for people struggling with alcohol use disorder. A study published in the Lancet found that participants taking semaglutide cut their reported monthly alcohol consumption by around 70%. The clinical trial, conducted at Copenhagen University Hospital–Bispebjerg and Frederiksberg, was the first double-blind randomized controlled study to pit the drug against a placebo in patients motivated to change.

Doctors first suspected GLP-1 RAs could treat addiction after noticing that patients prescribed the medication for blood sugar control were losing significant weight. It turned out the drugs act on the brain to curb compulsive behavior. Medics are now looking at whether these drugs can calm the reward circuits involved in substance use disorder. Previous research using Exenatide showed brain scans differed in reward response, even if drinking didn’t drop much. Semaglutide, which performs better than Exenatide in clinical trials, appeared to move the needle in real-world conditions.

This trial recruited volunteers specifically because they wanted to get better. People don’t lose weight by magic with these drugs; they still need to develop healthy habits. The researchers took a pragmatic approach, offering both groups regular cognitive behavioral therapy sessions in addition to their weekly injections. Given that every participant was motivated and the experimental design carefully accounted for a powerful placebo effect, the focus was on isolating the drug’s specific impact.

What makes these findings interesting is the overlap between the biology of eating and drinking. Both behaviors engage the brain’s reward pathways. If a drug can quiet the urge to eat, it stands to reason it might also dampen the urge to drink. The fact that the participants also smoked less often during the trial suggests the drug affects broader compulsive behaviors, though the effect on smoking was not statistically significant compared to the placebo group.

Measurable Results

The study involved 108 eligible volunteers who were divided equally between two groups. One group received weekly injections of saline for 26 weeks, while the other titrated up to 2.4 mg of semaglutide. At the end of the six-month period, the difference between the two groups was statistically significant. Participants on semaglutide had 41.1% fewer heavy drinking days than they started with, compared to a 26% reduction in the placebo group.

Those on the medication also saw physical changes. The semaglutide group reduced their waist circumference by an average of 12 cm, or about five inches, while the control group lost close to 4 cm. They cut their average number of units per drinking day by 3.5, whereas the placebo group left two more in the fridge. Overall, the semaglutide group reduced their total monthly alcohol consumption by around 72%, while the control group trimmed 46% off.

It is worth noting that the researchers used the Time Follow Back method to track drinking habits, asking participants to document their alcohol intake for the last 40 days each month. This method can sometimes encourage people to drink less simply because they are being observed, but the researchers were careful to account for this by collecting baseline data before the trial began. The results suggest that for a specific population of obese individuals with severe alcohol use disorder who are ready to make changes, the drug provides measurable support.

While this was a relatively small study with a homogenous population, it lays the groundwork for larger trials. The researchers cannot say yet whether GLP-1 RAs would work for people who are not obese, but the results look promising enough to warrant further investigation.